Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S ESR1 Mutant Breast Cancer Cells.
Young KS, Hancock GR, Fink E, Zigrossi A, Flowers B, Cooper DA, Nguyen VT, Martinez M, Mon KS, Bosland M, Zak D, Runde A, Sharifi MN, Kastrati I, Minh DDL, Kregel S, Fanning SW. Young KS, et al. Among authors: sharifi mn. Res Sq [Preprint]. 2024 Jun 25:rs.3.rs-4542467. doi: 10.21203/rs.3.rs-4542467/v1. Res Sq. 2024. PMID: 38978585 Free PMC article. Preprint.
Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S ESR1 Mutant Breast Cancer Cells.
Young KS, Hancock GR, Fink E, Zigrossi A, Flowers B, Cooper DA, Nguyen VT, Martinez M, Mon KS, Bosland M, Zak D, Runde A, Sharifi MN, Kastrati I, Minh DDL, Kregel S, Fanning SW. Young KS, et al. Among authors: sharifi mn. bioRxiv [Preprint]. 2024 Jun 2:2024.05.28.596307. doi: 10.1101/2024.05.28.596307. bioRxiv. 2024. PMID: 38854123 Free PMC article. Preprint.
A phenocopy signature of TP53 loss predicts response to chemotherapy.
Bakhtiar H, Sharifi MN, Helzer KT, Shi Y, Bootsma ML, Shang TA, Chrostek MR, Berg TJ, Carson Callahan S, Carreno V, Blitzer GC, West MT, O'Regan RM, Wisinski KB, Sjöström M, Zhao SG. Bakhtiar H, et al. Among authors: sharifi mn. NPJ Precis Oncol. 2024 Oct 2;8(1):220. doi: 10.1038/s41698-024-00722-7. NPJ Precis Oncol. 2024. PMID: 39358429 Free PMC article.
Clinical cell-surface targets in metastatic and primary solid cancers.
Sharifi MN, Shi Y, Chrostek MR, Callahan SC, Shang T, Berg TJ, Helzer KT, Bootsma ML, Sjöström M, Josefsson A, Feng FY, Huffman LB, Schulte C, Blitzer GC, Sodji QH, Morris ZS, Ma VT, Meimetis L, Kosoff D, Taylor AK, LeBeau AM, Lang JM, Zhao SG. Sharifi MN, et al. JCI Insight. 2024 Sep 24;9(18):e183674. doi: 10.1172/jci.insight.183674. JCI Insight. 2024. PMID: 39315546 Free PMC article.
A platform-independent AI tumor lineage and site (ATLAS) classifier.
Rydzewski NR, Shi Y, Li C, Chrostek MR, Bakhtiar H, Helzer KT, Bootsma ML, Berg TJ, Harari PM, Floberg JM, Blitzer GC, Kosoff D, Taylor AK, Sharifi MN, Yu M, Lang JM, Patel KR, Citrin DE, Sundling KE, Zhao SG. Rydzewski NR, et al. Among authors: sharifi mn. Commun Biol. 2024 Mar 13;7(1):314. doi: 10.1038/s42003-024-05981-5. Commun Biol. 2024. PMID: 38480799 Free PMC article.
Fragmentomic analysis of circulating tumor DNA-targeted cancer panels.
Helzer KT, Sharifi MN, Sperger JM, Shi Y, Annala M, Bootsma ML, Reese SR, Taylor A, Kaufmann KR, Krause HK, Schehr JL, Sethakorn N, Kosoff D, Kyriakopoulos C, Burkard ME, Rydzewski NR, Yu M, Harari PM, Bassetti M, Blitzer G, Floberg J, Sjöström M, Quigley DA, Dehm SM, Armstrong AJ, Beltran H, McKay RR, Feng FY, O'Regan R, Wisinski KB, Emamekhoo H, Wyatt AW, Lang JM, Zhao SG. Helzer KT, et al. Among authors: sharifi mn. Ann Oncol. 2023 Sep;34(9):813-825. doi: 10.1016/j.annonc.2023.06.001. Epub 2023 Jun 16. Ann Oncol. 2023. PMID: 37330052 Free PMC article.
Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study.
Kalra M, Henry E, McCann K, Karuturi MS, Bustamante Alvarez JG, Parkes A, Wesolowski R, Wei M, Mougalian SS, Durm G, Qin A, Schonewolf C, Trivedi M, Armaghani AJ, Wilson FH, Iams WT, Turk AA, Vikas P, Cecchini M, Lubner S, Pathak P, Spencer K, Koshkin VS, Labriola MK, Marshall CH, Beckermann KE; theMednet.org NCI-CCC Tumor Board Program Collaborative Group; Sharifi MN, Bejjani AC, Hotchandani V, Housri S, Housri N. Kalra M, et al. Among authors: sharifi mn. JMIR Cancer. 2022 May 19;8(2):e33859. doi: 10.2196/33859. JMIR Cancer. 2022. PMID: 35588361 Free PMC article.
A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782).
Leal TA, Sharifi MN, Chan N, Wesolowski R, Turk AA, Bruce JY, O'Regan RM, Eickhoff J, Barroilhet LM, Malhotra J, Mehnert J, Girda E, Wiley E, Schmitz N, Andrews S, Liu G, Wisinski KB. Leal TA, et al. Among authors: sharifi mn. Cancer Med. 2022 Nov;11(21):3969-3981. doi: 10.1002/cam4.4724. Epub 2022 Apr 8. Cancer Med. 2022. PMID: 35396812 Free PMC article. Clinical Trial.
25 results